drugset
drugset / Trial / NCT07230184

To Evaluate the Efficacy and Safety of Combination Therapy With B55R1 and B55R2 Compared to B55R1 Monotherapy in Patients With NPDR

NCT07230184 ↗

Phase 4 Completed 52 enrolled AJU Pharm Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is planned to evaluate the efficacy and safety of combination therapy with B55R1 and B55R2 compared to B55R1 monotherapy in patients with non-proliferative diabetic retinopathy (NPDR).

Timeline

Start
2022-04-28
Primary completion
2023-08-14
Completion
2024-08-16

Drugs

EvaluationDrugModalityDoseRoute
Subject B55R1 Unknown — Oral
Subject B55R2 Unknown — Oral

Indications

diabetic retinopathy